While gene sets derived from the analysis of differential expression often reveal a variety of pathways related to inflammation and innate immune responses, the disease module identified in this study exhibits the most significant enrichment for pathways targeted by state-of-the-art therapeutic solutions for AD, such as biologics targeting IL4-IL13 signalling (dupilumab and tralokinumab), and drugs targeting genes such as JAK1, JAK2, JAK3 and TYK2, which are pivotal actors in the Jak-Stat signalling pathway (barticitinib, upadacitinib and abrocitinib). This evidence concerns the gene IL13 and Alzheimer disease.